IL-6阻断通过降低分解代谢而非增加合成升高LDL:类风湿关节炎胆固醇变化的细胞因子特异性机制
该研究在11例活动性重度类风湿关节炎患者中开展脂蛋白动力学研究,比较托珠单抗治疗前后血脂变化。结果显示托珠单抗治疗后总胆固醇、LDL-c和HDL-c均升高,LDL分解代谢率从高分解状态降至接近正常人群水平,且该变化与急性期反应相关而非临床疾病活动度。
要点
- 活动性RA患者LDL-c降低源于LDL颗粒高分解代谢。
- IL-6阻断使LDL分解代谢正常化,与急性期反应相关而非临床疾病活动度。
- IL-6是炎症驱动血脂异常的关键驱动因子之一。
核心结论
- 活动性RA患者血清LDL-c降低由LDL颗粒高分解代谢所致。
- IL-6阻断使LDL分解代谢正常化,该效应与急性期反应相关而与临床评估的RA疾病活动度无关。
- IL-6是炎症驱动血脂异常的关键驱动因子之一。
研究设计与样本
- KALIBRA研究对11例活动性重度RA患者在基线和接受三次静脉托珠单抗输注后进行脂蛋白动力学研究。
- 主要结局指标为LDL的分数分解代谢率(FCR)。
主要发现
- 托珠单抗治疗后血清总胆固醇升高(4.8 vs 5.7 mmol/L,p=0.003)。
- 托珠单抗治疗后LDL-c升高(2.9 vs 3.4 mmol/L,p=0.014)。
- 托珠单抗治疗后HDL-c升高(1.23 vs 1.52 mmol/L,p=0.006)。
- LDL FCR从高分解状态降至接近正常人群水平(0.53 vs 0.27 pools/day,p=0.006)。
- FCR变化与血清LDL-c和C反应蛋白变化紧密相关,但与临床疾病活动指数无关。
临床怎么用
- 对于接受IL-6阻断治疗的RA患者,应关注血脂升高源于分解代谢正常化而非合成增加。
- 临床评估RA疾病活动度可能无法反映IL-6阻断对血脂代谢的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Patients with rheumatoid arthritis (RA) have reduced serum low-density lipoprotein cholesterol (LDL-c), which increases following therapeutic IL-6 blockade. We aimed to define the metabolic pathways underlying these lipid changes. METHODS: In the KALIBRA study, lipoprotein kinetic studies were performed on 11 patients with severe active RA at baseline and following three intravenous infusions of the IL-6R blocker tocilizumab. The primary outcome measure was the fractional catabolic rate (FCR) of LDL. RESULTS: Serum total cholesterol (4.8 vs 5.7 mmol/L, p=0.003), LDL-c (2.9 vs 3.4 mmol/L, p=0.014) and high-density lipoprotein cholesterol (1.23 vs 1.52 mmol/L, p=0.006) increased following tocilizumab therapy. The LDL FCR fell from a state of hypercatabolism to a value approximating that of the normal population (0.53 vs 0.27 pools/day, p=0.006). Changes in FCR correlated tightly with changes in serum LDL-c and C-reactive protein but not Clinical Disease Activity Index. CONCLUSIONS: Patients with RA have low serum LDL-c due to hypercatabolism of LDL particles. IL-6 blockade normalises this catabolism in a manner associating with the acute phase response (and thus hepatic IL-6 signalling) but not with RA disease activity as measured clinically. We demonstrate that IL-6 is one of the key drivers of inflammation-driven dyslipidaemia.
引用
- Robertson J, Porter D, Sattar N, et al. Interleukin-6 blockade raises LDL via reduced catabolism rather than via increased synthesis: a cytokine-specific mechanism for cholesterol changes in rheumatoid arthritis. Ann Rheum Dis. 2017. PMID: 28916714. doi:10.1136/annrheumdis-2017-211708
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。